Dr. Joshua Robert Veatch, MD, PhD

Dr. Veatch practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Dr. Veatch's NPI, 1407173826, was assigned on April 24, 2010. Dr. Veatch graduated from University of Washington School of Medicine in 2010. Dr. Veatch holds Washington license 60164370.

Dr. Veatch's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Dr. Veatch's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Dr. Veatch is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians. Dmand AI also links Dr. Veatch to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Veatch practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Veatch's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Veatch is licensed in Washington.

CMS data shows 141 Medicare services from Dr. Veatch across 3 procedure codes in 2024, for 69 Medicare patients. Medicare paid $11,840 for them. Every service was in an office.

CMS counts 69 Medicare patients who saw Dr. Veatch in 2024. The largest group is 65 to 74, with 37 patients. 68% of them have high blood pressure, and 61% have high cholesterol. Their average risk score is 1.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Veatch's median patient age at 73, with 40% women.

In 2024, Dr. Veatch wrote 37 Medicare Part D claims for 12 patients. 49% of them were for generic drugs. CMS names the drug for 22 of them, across 2 drugs with 11 or more claims each, at $450 in total drug cost. In 2020, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Veatch for performance year 2024, reported through an alternative payment model (APM). Dr. Veatch accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Veatch as offering telehealth.

Dmand AI links 19 papers to Dr. Veatch, published from 2017 to 2025. 2021 was the busiest year, with 3. The most frequent topics are Melanoma, Immune Checkpoint Inhibitors and Skin Neoplasms. Dr. Veatch has published most often in Cancer Immunol Immunother. Dr. Veatch's most frequent co-authors are Stanley R. Riddell, MD, Shailender Bhatia, MD and Sylvia Mina Lee, MD.

Dmand AI links Dr. Veatch to 1 clinical trial. Conditions studied include Carcinoma, Merkel Cell and Polyomavirus Infections.

CMS Open Payments shows 2 general payments to Dr. Veatch from 1 drug or device company in 2019. Food and beverage make up the largest share, 100% of the total. Genentech, Inc. paid the most, $368.

Dr. Veatch graduated from University of Washington School of Medicine in 2010.